Submission of the manuscript is online via e-mail or

Tel: +7 903 250 5288

Editorial Correspondence e-mail

Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail

Tel: +7 917 561 9505

SCImago Journal & Country Rank

    1. Moscow Regional Research and Clinical Institute («MONIKI») (Moscow, Russian Federation)
    2. A.I.Yevdokimov Moscow State University of Medicine and Dentistry (Moscow, Russian Federation)

    Keywords: neuroendocrine tumors, diarrhea, lanreotide Autogel, somatostatin analogs, antiproliferative effect

    Abstract:Neuroendocrine tumors (NET) are a rare, but dangerous disease, and often have malignant character. The frequency is about 35 cases at 100.000 population, with 2-5 new cases on 100.000 people a year. The majority of NET produce the active substances in various degree influencing exocrine function and motility of the gastrointestinal tract (GIT). The frequent clinical manifestation of NET is diarrhea. It is necessary to carry out a differential diagnosis of NET in patients with the persistent not stopped diarrhea and/or ulcer damage of a GIT. The purposes of treatment of NET are the elimination of primary tumor (and its metastasizes - if they are) and normalization of a hormonal background that leads to a regress of clinical symptoms. The randomized controlled studies PROMID and CLARINET with a high degree of substantiality have shown symptomatic improvement and significant anti-proliferative effect of somatostatin analogs in the treatment of NET. In the CLARINET study, the lanreotide Autogel was effective at a wide range of patients with highly - and moderate differentiated NET (Ki-67 <10%), including with primary tumor in a small intestine and pancreas, with a primary tumor of unknown localization, and with metastatic damage of a liver. Now somatostatin analogs are considered as the first line of drug treatment of patients with highly - and moderate differentiated NET of digestive tract regardless of the extent of metastatic damage of a liver.

      1. Rossana B, Silvia R, Mariangela T, et al. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy – A literature review.// Crit Rev Oncol Hematol. 2016 Feb; 98: 264–274.
      2. Kuz’minov A.E., Polozkova S. A., Orel N. F., Gorbunova V. A. Neuroendocrine tumors. Effective pharmacotherapy. 2012, no.34, pp.44–48.
      3. van der Zwan JM, Trama A, Otter R, Larrañaga N, Tavilla A, Marcos-Gragera R, Dei Tos AP, Baudin E, Poston G, Links T, RARECARE WG. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013 Jul; 49(11):2565–78.
      4. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18):3063–72.
      5. Sandvik OM, Søreide K, Gudlaugsson E, Kvaløy JT, Søreide JA Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria. Br J Surg. 2016 Feb; 103(3):226–32.
      6. Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013 Dec 21; 19(47):9012–9
      7. Tsai HJ, Wu CC, Tsai CR, Lin SF, Chen LT, Chang JS. The epidemiology of neuroendocrine tumors in Taiwan: a nation-wide cancer registry-based study. PLoS One. 2013; 8(4): e62487.
      8. Chauhan A, Yu Q, Ray N, Farooqui Z, Huang B, Durbin EB, Tucker T, Evers M, Arnold S, Anthony LB. Global burden of neuroendocrine tumors and changing incidence in Kentucky. Oncotarget. 2018 Apr 10;9(27):19245–19254. doi: 10.18632/oncotarget.24983.
      9. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients with Neuroendocrine Tumors in the United States. JAMA Oncol. 2017 Oct 1; 3(10):1335–1342.
      10. Klöppel G. Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visc Med. 2017 Oct;33(5):324–330. doi: 10.1159/000481390.
      11. Klimstra D.S., Modlin I. R., Coppola D., Lloyd R. V., Suster S. The Pathologic Classification of Neuroendocrine Tumors. A review of Nomenclature, Grading, and Staging Systems.// Pancreas, 2010, 39: 707–712.3. Cives M, Strosberg J. An Update on Gastroenteropancreatic Neuroendocrine Tumors.// Oncology (Williston Park). 2014 Sep 15; 28 (9): 749–756.
      12. Vinik AI, Chaya C. Clinical Presentation and Diagnosis of Neuroendocrine Tumors.// Hematol Oncol Clin North Am. 2016 Feb; 30 (1): 21–48.
      13. Halperin DM, Shen C, Dasari A, Xu Y, Chu Y, Zhou S, Shih YT, Yao JC. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017 Apr; 18(4):525–534.
      14. Boutzios G, Kaltsas G. Clinical Syndromes Related to Gastrointestinal Neuroendocrine Neoplasms. Front Horm Res. 2015;44:40–57. doi: 10.1159/000382053.
      15. Dedov I. I., Melnichenko G. A. Endocrinology: national leadership. Moscow, Geotar-media Publ., 2016, 1112 p.
      16. Pavel M, Baudin E, Couvelard A et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012; 95 (2): 157–76.
      17. Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Hematol Oncol Clin North Am. 2016 Feb; 30 (1): 103–18.
      18. Demirkan BH, Eriksson B. Systemic treatment of neuroendocrine tumors with hepatic metastases. Turk J Gastroenterol. 2012; 23 (5): 427–437.
      19. Shpakov A. O. Somatostatin receptors and signaling cascades coupled to them. Journal of Evolutionary Biochemistry and Physiology. 2012 48(4):329–341 ru
      20. Schally AV. Oncological applications of somatostatin analogues.// Cancer Res 1988; 1: 6977–6985.
      21. Modlin IM, Kidd M, Drozdov I, Siddique ZL, Gustafsson BI. Pharmacotherapy of neuroendocrine cancers.// Expert Opin Pharmacother 2008; 9 (15): 2617–2626.
      22. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.// Aliment Pharmacol Ther. 2010 Jan 15; 31 (2): 169–188.
      23. Orlova R. V., Novik A. V. Modern approaches of medicinal treatment of generalized forms of neuroendocrine tumors. Symptomatic therapy of syndromes in neuroendocrine neoplasias. Practical oncology. 2005;6(4):240–246.
      24. Karakaxas D, Gazouli M, Liakakos T, et al. Pancreatic neuroendocrine tumors: current opinions on a rare, but potentially curable neoplasm.// Eur J Gastroenterol Hepatol. 2014; 26 (8): 826–35.
      25. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.// J Clin Oncol, 2009; 27: 4656–4663.
      26. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.// New Engl J Med, 2014; 371: 224–233. doi: 10.1056/NEJMoa1316158.
      27. Buil-Bruna N, Dehez M, Manon A, Nguyen TX, Trocóniz IF. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors. AAPS J. 2016 May;18(3):703–12. doi: 10.1208/s12248–016–9884–3.
      28. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P CLARINET Investigators. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. Endocr Relat Cancer. 2016 Mar;23(3):191–9. doi: 10.1530/ERC-15–0490.
      29. Wolin EM, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E. Final progression-free survival analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors: the CLARINET extension study. J Clin Oncol. 2017, Vol. 35, no. 15_suppl: 4089–4089. DOI: 10.1200/JCO.2017.35.15_suppl.4089
      30. Phan AT, Caplin ME, Pavel ME, Cwikla J B, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Gomez-Panzani E, Ruszniewski PB. Effects of lanreotide Depot/Autogel in pancreatic neuroendocrine tumors: a subgroup analysis from the CLARINET study. J Clin Oncol. 2015. Vol. 33, no. 3_suppl:233–233. DOI: 10.1200/jco.2015.33.3_suppl.233
      31. Cwikla JB, Wolin EM, Pavel M, Phan AT, Raderer M, Sedláčková E, Cadiot G, Capdevila J, Rindi G, Lombard-Bohas C, Liyanage N, Truong Thanh X–M, Ruszniewski P, Caplin M. Ann Oncol. 2017. Vol. 28, Issue suppl_5,
      32. Massironi S, Conte D, Rossi RE. Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.// Scand J Gastroenterol. 2016; 51 (5): 513–523.
      33. Saif MW. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.// Expert Opin Pharmacother. 2016;17 (3): 443–456.
      34. Kos-Kudła B. Treatment of neuroendocrine tumors: new recommendations based on the CLARINET study.// Contemp Oncol (Pozn). 2015;19 (5): 345–9.
      35. Mehrvarz Sarshekeh A, Halperin DM, Dasari A. Update on management of midgut neuroendocrine tumors. Int J Endocrine Oncol. 2016;3(2):175–189. doi:10.2217/ije-2015–0004.

    Full text is published :
    Ilovayskaya I. A. DIARRHEA AS A CLINICAL MARKER OF NEUROENDOCRINE TUMORS. Experimental and Clinical Gastroenterology Journal. 2018;154(06):143-149
    Read & Download full text

    1. North-western State Medical University n. a. I. I. Mechnikov (St. Petersburg, Russian Federation)
    2. Federal State Autonomous Educational Institution of Higher Education I. M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Moscow, Russian Federation)

    Keywords: ursodeoxycholic acid, Grinterol®, cytolysis syndrome, cholestasis syndrome

    Abstract:The influence of therapy with ursodeoxycholic acid Grinterol® on the clinical and biochemical parameters of patients with hepatobiliary pathology under conditions of real polyclinic practice was studied. The study involved 300 centers in 25 cities of the Russian Federation. The number of participants was 10213 patients. The study included patients with non-alcoholic fatty liver disease, alcoholic liver disease, chronic viral hepatitis, drug damage to the liver, cirrhosis, сholecystitis with biliary sludge. An assessment of the dynamics of clinical symptoms and biochemical markers of hepatic cytolysis and cholestasis demonstrated the high clinical effectiveness of therapy with Grinterol®, safety and the minimum side effects in all the examined groups. According to the results of the study, the use of the medicinal preparation Grinterol® seems very appropriate for the treatment of diseases of the hepatobiliary system.

      1. Grinevich V. B., Sas E. I. Physiological effects of bile acids. RMJ. Medical review. 2017. No. 2, Pp. 87–91. (in Russian)
      2. Lapina TL, Kartavenko IM. Ursodeoxycholic acid: effect on the mucosa of the upper gastrointestinal tract. Ros Zhurn Gastroenterologii Gepatologii Koloproktologii. 2007; no. 17(6), pp. 51–7. (In Russian)
      3. I. I. Chukaeva, N. V. Orlova. Clinical management of patient with refractory gastroesophageal reflux disease. Medicinskij alfavit 2017, vol. 2 no. 34 pp 22–27 (In Russian)
      4. McQuaid KR, Laine L, Fennerty MB, Souza R, Spechler SJ. Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther., 2011 Jul, 34(2): 146–65.
      5. Banerjee B, Shaheen NJ, Martinez JA et al. Clinical Study of Ursodeoxycholic Acid in Barrett’s Esophagus Patients. Cancer Prev Res (Phila), 2016 Feb 23. pii: canprevres.0276.2015.
      6. Ilchenko А. А. Bolezni zhelchnogo puzyrya i zhelchnykh putej [Diseases of the gallbladder and biliary tracts], Meditsinskoe informatsionnoe agentstvo, 2011, p. 880 (in Russian)
      7. Wijaya I. The Role of Ursodeoxycholic Acid in Acute Viral Hepatitis: an Evidence-based Case Report. Acta Med Indones., 2015 Oct, 47(4): 352–7.
      8. Rejzis А.R., Matanina N. V., Nikitina T. S., et al. Primenenie preparatov ursodezoksikholevoj kisloty (Ursosana) v lechenii ostrykh i khronicheskikh virusnykh gepatitov [The use of drugs ursodeoxycholic acid (ursosan) in the treatment of acute and chronic viral hepatitis], informatsionnoe pis’mo FGUN CNIIE Rospotrebnadzora, 2006, pp. 1–19 (in Russian)
      9. T.L. Lapina, I. M. Kartavenko, V. T. Ivashkin Pathogenic and therapeutic role of bile acids at reflux-gastritis, Russian Journal of Gastroenterology, Hepatology, Coloproctology, 2016 vol. 25, no. 1, pp. 86–93 (in Russian)
      10. Mehtiyev S.N., Mehtiyev O. A. Algorithm for the management of patients with functional disorders of the biliary tract. Lechaschiy Vrach, 2013, no. 4, pp. 52–59. (in Russian)
      11. O. N. Minushkin, L. V. Maslovsky, O. A. Eremenko, O. F. Shaposhnikova, M. S. Makarova. Biliary sludge as the initial stage of cholelithiasis. Therapy and prevention, Meditsinskiy Sovet, 2017, no. 5, pp. 65–69 (in Russian).
      12. Lazebnik L.B. et al. Nonalcoholic fatty liver disease: clinic, diagnostics, treatment, Eksperimental’naya i Klinicheskaya Gastroenterologiya 2017; 138 (2), pp. 22–37 (in Russian)
      13. Bojtsov S. А., Chuchalin А. G. Dispansernoe nablyudenie bol’nykh khronicheskimi neinfektsionnymi zabolevaniyami i patsientov s vysokim riskom ikh razvitiya [Clinical follow-up of patients with chronic non-infectious diseases and patients at high risk of their development], Moscow, 2014, p. 112 (In Russian)
      14. A.A. Shipovskaya, O. P. Dudanova. Intrahepatic cholestasis in nonalcoholic fatty liver disease. Therapeutic Archive, 2018, vol. 90, no. 2, pp. 69–74 (in Russian)
      15. Kazyulin A. N. Place of ursodeoxycholic acid in the therapy of non-alcoholic fatty liver disease at different stages: steatosis, steatohepatitis, fibrosis / cirrhosis, RMJ. 2017. No. 17. pp. 1248–1257 (in Russian)
      16. Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract., 2016 Apr, 70(4): 302–11.
      17. Plevris J. N., Hayes P. C., Bouchier I. A. D. Ursodeoxycholic acid in the treatment of alcoholic liver disease. Gastroenterol // Hepatol. 1991; 3: 6536–6541
      18. Roma M.G., Toledo F. D., Boaglio A. C. et al. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications // Clin. Sci. (Lond.). 2011. Vol. 121. № 12. P. 523–544.
      19. Landar’ L. N., CHudakov N. V. Alcoholic liver disease, therapeutic treatment, Nauka i obrazovanie: sokhranyaya proshloe, sozdayom budushhee, 2018, pp. 210–214. (in Russian)
      20. V. M. Makhov, L. N. Ugryumova, A. A. Balakhonov, Z. A. Mamieva Ursodezoksiholevaja acid: therapist’s view, Meditsinskiy Sovet, 2017. No. 5. Pp. 112–116 (in Russian)
      21. Vertkin A.L., Torubarov S. F. Alkogol’-assotsiirovannye sostoianiia v klinike vnutrennikh boleznei. Opredelenie, taktika vedeniia. Ambulatornyi priem. 2017; 1 (3): 57–62. (in Russian)
      22. O. N. Minushkin, I. V. Zverkov, Yu. S. Skibina. Some approaches to treatment of patients with chronic (biliary) reflux gastritis, Medical Alphabet, 2017, vol. 2, no. 19, pp. 28–31. (in Russian)
      23. Polunina Т. Е. Biliary dysfunction. Rome Consensus IV. Therapy. 2017;6(16), pp. 100–112. (in Russian)

    Full text is published :
    Read & Download full text